Zygem to Sell Rubicon Kits Down Under

Jan 29, 2010

NEW YORK (GenomeWeb News) – Zygem will market Rubicon Genomics' PicoPlex single-cell amplification kits in Australia and New Zealand, under a non-exclusive agreement, Rubicon said today.

Rubicon's kits are used to amplify small clinical samples into large amounts of pure DNA, and they are licensed and sold to clinical markets for pre-implantation and prenatal testing, cancer testing, and for making diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Featured White Papers

Discovering Neuronal Cell Types

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Main menu